Manfred Gröppel, Ph.D.

As a co-founder of Immunic (Nasdaq: IMUX), I was part of the success story of bringing a start-up company through a reverse takeover to a Nasdaq listed biotech company valued up to more than a half billion dollar in less than 3 years.

Experienced business development professional with a track record of successful licensing transactions in the healthcare industry worldwide (EU, USA, Japan and China). More than 20 years of BD/L leadership experience with a strong scientific background and sound knowledge in drug discovery, product development, manufacturing processes, CMC, patents, financing, clinical trial design, regulatory and project valuation.

Excellent personal contact network and the proven ability to close clinical stage deals.

  • More than 20 closed deals including Yakult Honsha, Nycomed, Serono, Schwarz Pharma, Sanofi-Aventis, Boehringer Ingelheim, Schering, Astra Zeneca, Solvay, Recordati, Esteve, …

  • Out-licensing of Japanese rights of Resminostat (phase II) to Yakult Honsha in deal worth more than $192m plus royalties, featured on the front page of Bioworld, April 2011

  • Successfully in-licensed 8 projects, currently in 5 clinical studies, for €14m in a one-time payment without further milestones and royalties

  • Out-licensing of clinical stage project to Serono worth $67m plus royalties

  • Exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease from Daiichi Sankyo for a one-time option execution payment as well as a range of milestone payments and royalties.

Selected Transactions and Deal Activities